e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Bronchodilator treatment for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pharmacokinetics and safety of aclidinium bromide in young and elderly patients with COPD
S. de la Motte, J. Beier, K. Schmid, J. Ho, S. Pascual, J. Maria Jansat, E. Garcia Gil (Munich, Wiesbaden, Germany; New Jersey, United States Of America; Barcelona, Spain)
Source:
Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Session:
Bronchodilator treatment for asthma and COPD
Session type:
Thematic Poster Session
Number:
1194
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. de la Motte, J. Beier, K. Schmid, J. Ho, S. Pascual, J. Maria Jansat, E. Garcia Gil (Munich, Wiesbaden, Germany; New Jersey, United States Of America; Barcelona, Spain). Pharmacokinetics and safety of aclidinium bromide in young and elderly patients with COPD. Eur Respir J 2010; 36: Suppl. 54, 1194
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010
Pharmacokinetics of tiotropium administered by Respimat in adolescent asthma patients
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010
Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
The pharmacokinetics of inhaled NVA237 in COPD patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Tiotropium bromide: Efficacy and safety in complex treatment of COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Population pharmacokinetics of nebulized arformoterol in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006
Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 356s
Year: 2007
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012
The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept